Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma

October 30, 2018

Follow-on drugs, also referred to as ‘next-generation drugs’, are ‘an established practice’ among drug innovators. They are one of the most effective R&D strategies implemented by drug innovators, and can be considered a cannibalization or switching strategy. In a nutshell, it is a timely switch from a mature/firstgeneration drug to its next-generation, improved version. Given the fixed patent term and limited market exclusivity of drugs, cannibalization has been instrumental in maintaining the market share for drug makers.

Spotlight

Infinity Pharma

Overcoming barriers, pushing boundaries and bringing the latest to the masterful market is the goal of Infinity Pharma®. A brand that has in its DNA the innovative spirit and evolution as fundamental pieces, capable of transforming the segment leading brand, reference in prevention and innovation of individualized treatment, into a business model with an identity that represents a new vision for the future with infinite possibilities. Inspired by infinity, the company begins a new cycle and aims to exceed the expectations of master consumers, doctors and pharmacists, combining quality, research and technology in new proposals for individualization, with unique assets. With brand-leading experience, Infinity Pharma® has established itself as a company specializing in individualized treatment, reference in prevention and innovation in products, services and concepts for health professionals and the master market.

OTHER WHITEPAPERS
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.

Read More
news image

Shining a Light on Lipid Nanoparticle Characterization

whitePaper | October 3, 2022

Next-Generation Synthetic Biology Workflow Platform Codex DNA’s BioXp 9600 system is a next-generation high throughput platform intended for automated synthesis of gene fragments and clones from digital sequences.

Read More
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More

Spotlight

Infinity Pharma

Overcoming barriers, pushing boundaries and bringing the latest to the masterful market is the goal of Infinity Pharma®. A brand that has in its DNA the innovative spirit and evolution as fundamental pieces, capable of transforming the segment leading brand, reference in prevention and innovation of individualized treatment, into a business model with an identity that represents a new vision for the future with infinite possibilities. Inspired by infinity, the company begins a new cycle and aims to exceed the expectations of master consumers, doctors and pharmacists, combining quality, research and technology in new proposals for individualization, with unique assets. With brand-leading experience, Infinity Pharma® has established itself as a company specializing in individualized treatment, reference in prevention and innovation in products, services and concepts for health professionals and the master market.

Events